Investor Relations

Who is BrainsWay?

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.

The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.

BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Latest Releases

May 11, 2022

BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive

Read More

May 9, 2022

BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales

Veteran Medical Device Industry Sales and Marketing Executive Has Over 20 Years of Experience BURLINGTON, Mass. and JERUSALEM, May 09, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments

Read More

May 4, 2022

BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Additional presentations will highlight the utility of Deep TMS™ in Smoking Addiction and OCD BURLINGTON, Mass. and JERUSALEM, May 04, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments

Read More

For more information please contact:

Tel: +1-844-386-7001
Tel: +972-2-647-6010
Email: ir@brainsway.com